Noble Capital initiated coverage of Cardiff Oncology (CRDF) with an Outperform rating and $12 price target Cardiff is developing onvansertib for the treatment of multiple cancer indications, with the lead program in metastatic colorectal cancer for patients with a mutation that makes the cancer more aggressive and difficult to treat, the analyst noted. The firm values shares based on estimated FY30 EPS of $2.30 per share, discounted at 30% per year to allow for clinical and regulatory risks, the analyst says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology: Promising Clinical Results and Strong Financial Position Justify Buy Rating
- Cardiff Oncology Reports Increased Losses Amid Ongoing Trials
- Cardiff Oncology’s Promising Future: Buy Rating Backed by Strong Financials and Onvansertib’s Clinical Success
- Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M
- Cardiff Oncology reports Q3 EPS (17c), consensus (21c)